OBJECTIVE: The purpose of the present study was to evaluate the efficacy of divalproex for reducing aggressive behavior among children 6 to 13 years old with attention deficit hyperactivity disorder (ADHD) and a disruptive disorder whose chronic aggression was underresponsive to a prospective psychostimulant trial. METHOD: Children received open stimulant treatment during a lead-in phase that averaged 5 weeks. Agent and dose were assessed weekly and modified to optimize response. Children whose aggressive behavior persisted at the conclusion of the lead-in phase were randomly assigned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 weeks. Families received weekly behavioral therapy throughout the trial. The primary outcome measure was the proportion of children whose aggressive behavior remitted, defined by post-trial ratings of negligible or absent aggression. RESULT: A significantly higher proportion of children randomly assigned to divalproex met remission criteria (eight out of 14 [57%]) than those randomly assigned to placebo (two out of 13 [15%]). Divalproex was generally well tolerated. CONCLUSIONS: Among children with ADHD whose chronic aggressive behavior is refractory to optimized stimulant treatment, the addition of divalproex increases the likelihood that aggression will remit. A larger trial is necessary to specify with greater precision the magnitude of benefit for adjuvant divalproex.
RCT Entities:
OBJECTIVE: The purpose of the present study was to evaluate the efficacy of divalproex for reducing aggressive behavior among children 6 to 13 years old with attention deficit hyperactivity disorder (ADHD) and a disruptive disorder whose chronic aggression was underresponsive to a prospective psychostimulant trial. METHOD:Children received open stimulant treatment during a lead-in phase that averaged 5 weeks. Agent and dose were assessed weekly and modified to optimize response. Children whose aggressive behavior persisted at the conclusion of the lead-in phase were randomly assigned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 weeks. Families received weekly behavioral therapy throughout the trial. The primary outcome measure was the proportion of children whose aggressive behavior remitted, defined by post-trial ratings of negligible or absent aggression. RESULT: A significantly higher proportion of children randomly assigned to divalproex met remission criteria (eight out of 14 [57%]) than those randomly assigned to placebo (two out of 13 [15%]). Divalproex was generally well tolerated. CONCLUSIONS: Among children with ADHD whose chronic aggressive behavior is refractory to optimized stimulant treatment, the addition of divalproex increases the likelihood that aggression will remit. A larger trial is necessary to specify with greater precision the magnitude of benefit for adjuvant divalproex.
Authors: R L Findling; N K McNamara; L A Branicky; M D Schluchter; E Lemon; J L Blumer Journal: J Am Acad Child Adolesc Psychiatry Date: 2000-04 Impact factor: 8.829
Authors: Kimberly A Stigler; Lael A Desmond; David J Posey; Ryan E Wiegand; Christopher J McDougle Journal: J Child Adolesc Psychopharmacol Date: 2004 Impact factor: 2.576
Authors: James G Waxmonsky; Daniel A Waschbusch; Peter Belin; Tan Li; Lysett Babocsai; Hugh Humphery; Meaghan E Pariseau; Dara E Babinski; Martin T Hoffman; Jenifer L Haak; Jessica R Mazzant; Gregory A Fabiano; Jeremy W Pettit; Negar Fallahazad; William E Pelham Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-12-28 Impact factor: 8.829
Authors: Amy E West; Sally M Weinstein; Christine I Celio; David Henry; Mani N Pavuluri Journal: J Child Adolesc Psychopharmacol Date: 2011-12-02 Impact factor: 2.576
Authors: Joseph C Blader; Steven R Pliszka; Vivian Kafantaris; Carmel A Foley; Judith A Crowell; Gabrielle A Carlson; Colin L Sauder; David M Margulies; Christa Sinha; Jeffrey Sverd; Thomas L Matthews; Brigitte Y Bailey; W Burleson Daviss Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-09-25 Impact factor: 8.829
Authors: Joseph C Blader; Steven R Pliszka; Vivian Kafantaris; Colin Sauder; Jonathan Posner; Carmel A Foley; Gabrielle A Carlson; Judith A Crowell; David M Margulies Journal: J Child Adolesc Psychopharmacol Date: 2016-01-08 Impact factor: 2.576
Authors: Raman Baweja; Peter J Belin; Hugh H Humphrey; Lysett Babocsai; Meaghan E Pariseau; Daniel A Waschbusch; Martin T Hoffman; Opeolowa O Akinnusi; Jenifer L Haak; William E Pelham; James G Waxmonsky Journal: J Child Adolesc Psychopharmacol Date: 2016-01-15 Impact factor: 2.576